Program
Pn-MAPS30plus
A development code.
Its studies are mostly in Pneumonia, Bacterial, led by GlaxoSmithKline.
Furthest: phase 1, since Aug 4, 20254 company-led studies, 3 open or runningNext primary completion: Nov 19, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 43 open or running | phase 1since Aug 4, 2025 | Aug 4, 2025 | Nov 19, 2026phase 1 · NCT07428759 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 4, 2025First study: phase 1 study in Pneumonia, BacterialFirst studyNCT07105722 · 127 enrolled · Australia
- Feb 6, 20263 phase 1 studies in Pneumonia, BacterialNCT07406347, NCT07406334, NCT07428759
Ahead
- Nov 19, 2026Primary completion: phase 1 study in Pneumonia, BacterialNCT07428759
- Feb 22, 2027Primary completion: phase 1 study in Pneumonia, BacterialNCT07406334
- Oct 18, 2028Primary completion: phase 1 study in Pneumonia, BacterialNCT07406347
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07428759Pneumonia, Bacterial · Australia | 1 | Active, not recruiting | Nov 19, 2026 | 122 |
| NCT07406347Pneumonia, Bacterial | 1 | Not yet recruiting | Oct 18, 2028 | 60 |
| NCT07406334Pneumonia, Bacterial · South Africa | 1 | Active, not recruiting | Feb 22, 2027 | 46 |
| NCT07105722Pneumonia, Bacterial · Australia | 1 | Completed | May 6, 2026 | 127 |
How it is read
Names in the registry
- “Pn-MAPS30plus”, 4 entries
Codes read as this program: PNMAPS30PLUS.
Conditions, from the studies’ own filings
- Pneumonia, Bacterial, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.